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CLINICAL RESEARCH CORONARY ARTERY DISEASERisk Score for Vasospastic Angina 1144
Yusuke Takagi, Jun Takahashi, Satoshi Yasuda, Satoshi Miyata, Ryusuke Tsunoda, Yasuhiro Ogata,
Atsushi Seki, Tetsuya Sumiyoshi, Motoyuki Matsui, Toshikazu Goto, Yasuhiko Tanabe, Shozo Sueda,
Toshiaki Sato, Satoshi Ogawa, Norifumi Kubo, Shin-ichi Momomura, Hisao Ogawa,
Hiroaki Shimokawa, for the Japanese Coronary Spasm Association
The aim of the present study was to develop a comprehensive clinical risk score for
vasospastic angina (VSA) patients. A total of 1,429 patients (median age 66 years,
median follow-up 32 months) from the multicenter registry study by the Japanese Coronary
Spasm Association were utilized. Using a multivariable Cox proportional hazards model,
7 predictors of major adverse cardiac events (MACE) were deﬁned. An integer score was
assigned to each predictor proportional to the respective adjusted hazard ratio; history of out-
of-hospital cardiac arrest (4 points), smoking, angina at rest alone, organic coronary stenosis,
multivessel spasm (2 points each), ST-segment elevation during angina, and beta-blocker use
(1 point each). The incidence of MACE in the low-risk (score 0 to 2), intermediate-risk
(score 3 to 5), and high-risk (score 6 or more) patients was 2.5%, 7.0%, and 13%, respectively.
The average prediction rate of the scoring system in the internal training and validation sets
were 86.6% and 86.5%, respectively. The authors have developed a novel scoring system,
which may provide a comprehensive risk assessment and prognostic stratiﬁcation for VSA
patients.CARDIOMETABOLIC RISKETC-1002 Treatment for Hypercholesterolemia 1154
Christie M. Ballantyne, Michael H. Davidson, Diane E. MacDougall, Harold E. Bays,
Lorenzo A. DiCarlo, Noah L. Rosenberg, Janice Margulies, Roger S. Newton
ETC-1002 is a small molecule that modulates pathways of cholesterol, fatty acid, and
carbohydrate metabolism. This study evaluates the lipid-altering efﬁcacy and safety of
ETC-1002 in subjects with hypercholesterolemia. A total of 177 individuals with elevated
low-density lipoprotein cholesterol (LDL-C) (130 to 222 mg/dl), and normal and elevated
triglycerides were randomized to receive ETC-1002 or placebo for 12 weeks. ETC-1002 at
40, 80, and 120 mg lowered LDL-C by 18%, 25%, and 27%, respectively. ETC-1002 also
lowered apolipoprotein B, non–high-density lipoprotein cholesterol, and LDL particle
number in a dose-dependent manner. The authors concluded that ETC-1002 signiﬁcantly
lowered LDL-C levels up to 27% across a broad range of baseline triglycerides and was
generally safe and well tolerated.
Editorial Comment: John P. Kane, p. 1163(continued on page A-32)
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Bonnie Ky, Benjamin French, Abigail May Khan, Ted Plappert, Andrew Wang, Julio A. Chirinos,
James C. Fang, Nancy K. Sweitzer, Barry A. Borlaug, David A. Kass, Martin St. John Sutton,
Thomas P. Cappola
The authors compare the physiological determinants of ejection fraction (EF), namely
ventricular size, contractile function, and ventricular-arterial (VA) interaction and their
association with clinical outcomes in chronic heart failure (HF). A total of 466 patients with
chronic systolic HF (median EF 27%) underwent echocardiographic studies and quantitative
measures of EF were derived. Over a median follow-up of 3.4 years, there were 76 deaths,
52 transplants, 14 VAD placements, and 648 cardiac hospitalizations. EF was independently
associated with death, transplantation, and ventricular assist device placement (adjusted
hazard ratio [HR]: 3.0, comparing third vs. ﬁrst tertile) as were end-diastolic volume
(HR: 2.6), contractile function of the left ventricle as measured by end-systolic pressure
volume intercept (V0) (HR: 3.6), and ventricular arterial coupling (Ea/Eessb) (HR: 2.1).
Contractile function as measured by the end-systolic pressure volume relation slope (Eessb)
was not signiﬁcantly associated with adverse outcome. The authors conclude that left
ventricular size, V0, and VA coupling are associated with prognosis in systolic HF. VA
coupling via Ea/Eesb additionally can be used to gauge prognosis.
Editorial Comment: Daniel Burkhoff, p. 1173HEART FAILUREUrine Output in Acute Decompensated Heart Failure 1177
Stephen S. Gottlieb, Amanda Stebbins, Adriaan A. Voors, Vic Hasselblad, Justin A. Ezekowitz,
Robert M. Califf, Christopher M. O’Connor, Randall C. Starling, Adrian F. Hernandez
The authors of the study investigate whether nesiritide increases diuresis in congestive heart
failure (CHF) patients. A total of 4,881 patients that had data available on diuretic dose and
urine output from the ASCEND trial were evaluated. The median 24 h urine output was
2,280 ml with nesiritide and 2,200 ml with placebo. Loop diuretic dose (furosemide
equivalent) was 80 mg with both nesiritide and placebo. The authors conclude that nesiritide
did not increase urine output in patients with acute decompensated heart failure. Higher
diuretic dose was a strong predictor of higher urine output, but neurohormonal activation
(as evidenced by blood urea nitrogen concentration) and lower blood pressure limited
diuresis.
Editorial Comment: Wilfried Mullens, Frederik H. Verbrugge, p. 1184(continued on page A-33)
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K. E. Juhani Airaksinen, Toni Grönberg, Ilpo Nuotio, Marko Nikkinen, Antti Ylitalo,
Fausto Biancari, Juha E. K. Hartikainen
The study evaluates the incidence and risk factors of thromboembolic complication after
cardioversion of acute atrial ﬁbrillation (<48 h). Embolic complications were evaluated
during the 30 days after 5,116 cardioversions in 2,481 patients with neither oral
anticoagulation nor periprocedural heparin therapy. There were 38 (0.7%) deﬁnite
thromboembolic events (31 strokes) within 30 days (median 2 days, mean 4.6 days) after
cardioversion. In addition, 4 patients suffered transient ischemic attacks after cardioversion.
Classiﬁcation tree analysis showed that the highest risk of thromboembolism (98%) was
observed among patients with heart failure and diabetes, whereas patients with no heart
failure and age <60 years had the lowest risk of thromboembolism (0.2%). The authors
conclude that the incidence of post-cardioversion thromboembolic complications is high in
certain subgroups of patients when no anticoagulation is used after cardioversion of acute
atrial ﬁbrillation.
Editorial Comment: Nikolaos Dagres, Jelena Kornej, Gerhard Hindricks, p. 1193HEART RHYTHM DISORDERSPVC Ablation With Structural Heart Disease 1195
Diego Penela, Carine Van Huls Vans Taxis, Luis Aguinaga, Juan Fernández-Armenta,
Lluis Mont, Maria Angels Castel, Magda Heras, Jose María Tolosana, Marta Sitges,
Augusto Ordóñez, Josep Brugada, Katja Zeppenfeld, Antonio Berruezo
Ablation of premature ventricular contractions complexes (PVCs) in patients with left
ventricular (LV) dysfunction is usually restricted to patients with suspected PVC-induced
cardiomyopathy. This study was performed to assess the beneﬁt of PVC ablation in patients
with frequent PVCs and LV dysfunction regardless of previous structural heart disease
(SHD) diagnosis. A total of 80 consecutive patients with frequent PVCs and LV dysfunction
were included. Twenty-seven (34%) patients had a diagnosis of SHD. Successful sustained
ablation (SSA) was achieved in 53 (66%) patients, and left ventricular ejection fraction
(LVEF) improved from 33.7  8% to 43.8  9.4% at 6 and 12 months, respectively. A 13%
baseline PVC burden had 100% sensitivity and 85% speciﬁcity to predict an absolute increase
5% in LVEF after SSA. The authors conclude that independent of the presence of SHD,
the SSA of frequent PVCs in patients with depressed LVEF induced a progressive clinical
and functional improvement. Improvement in heart failure parameters was related to baseline
PVC burden and persistence of ablation success.(continued on page A-34)
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Jannet A. Eindhoven, Annemien E. van den Bosch, Titia P. E. Ruys, Petra Opic, Judith A. A. E. Cuypers,
Jackie S. McGhie, Maarten Witsenburg, Eric Boersma, Jolien W. Roos-Hesselink
The aim of this study was to determine the value of N-terminal pro–B-type natriuretic
peptide (NT-proBNP) in adults with congenital heart disease (CHD) and investigate its
relation with ventricular function and exercise capacity. Echocardiography, exercise testing,
and NT-proBNP measurements were performed in 475 consecutive adult CHD patients.
The median NT-proBNP level was 15.1 pmol/l. Highest NT-proBNP levels were observed
in patients with Fontan circulation (36.1 pmol/l) and systemic right ventricle (31.1 pmol/l);
lowest levels were seen in patients with aortic coarctation (7.3 pmol/l). NT-proBNP levels
varied and correlated with various echocardiographic parameters in each congenital heart
lesion. The authors conclude that NT-proBNP levels in adult CHD patients differ per
diagnosis and are related to echocardiographic parameters and exercise capacity. Disease-
speciﬁc correlations contribute to the understanding of the main hemodynamic problem
per diagnosis.
